| 许康康,韩 波,寒 溪,石冰洁,张文博,李 宛.雷珠单抗联合Ahmed青光眼阀植入术对新生血管性青光眼患者眼动脉血流动力学和血清VEGF、PDGF的影响[J].,2022,(12):2250-2254 |
| 雷珠单抗联合Ahmed青光眼阀植入术对新生血管性青光眼患者眼动脉血流动力学和血清VEGF、PDGF的影响 |
| Effects of Leizumab Combined with Ahmed Glaucoma Valve Implantation on Ocular Artery Hemodynamics and Serum VEGF and PDGF in Patients with Neovascular Glaucoma |
| 投稿时间：2021-12-08 修订日期：2021-12-31 |
| DOI：10.13241/j.cnki.pmb.2022.12.010 |
| 中文关键词: 雷珠单抗 Ahmed青光眼阀植入术 新生血管性青光眼 疗效 血流动力学 VEGF PDGF |
| 英文关键词: Leizumab Ahmed glaucoma valve implantation Neovascular glaucoma Efficacy Hemodynamics VEGF PDGF |
| 基金项目:国家自然科学基金项目（81400378） |
|
| 摘要点击次数: 767 |
| 全文下载次数: 408 |
| 中文摘要: |
| 摘要 目的：观察雷珠单抗联合Ahmed青光眼阀植入术治疗新生血管性青光眼（NVG）的疗效及对眼动脉血流动力学和血清血管内皮生长因子（VEGF）、血小板衍生生长因子（PDGF）的影响。方法：选择2018年4月~2021年2月期间华中科技大学同济医学院附属协和医院眼科收治的NVG患者60例94眼，采用随机数字表法将患者分为对照组和研究组，分别为30例48眼和30例46眼。对照组患者予以Ahmed青光眼阀植入术，研究组眼内注射雷珠单抗一周后再行Ahmed青光眼阀植入术，观察治疗效果，对比两组眼动脉血流动力学和血清VEGF、PDGF，观察虹膜与前房角新生血管消退率及并发症发生率。结果：研究组的疗效明显优于对照组（P<0.05）。研究组治疗后3个月血流阻力系数（RI）低于对照组，收缩期峰值流速（PSV）、舒张末期流速（EDV）高于对照组（P<0.05）。治疗后3个月两组VEGF、PDGF均下降，且研究组低于对照组（P<0.05）。治疗后3个月两组眼压下降，视力升高，且研究组的改善程度优于对照组（P<0.05），研究组虹膜与前房角新生血管消退率高于对照组（P<0.05）。研究组的并发症发生率少于对照组（P<0.05）。结论：NVG采用Ahmed青光眼阀植入术联合雷珠单抗治疗，可有效恢复视力、眼压，具有更好的疗效，这可能与联合治疗可改善眼动脉血流动力学及血清VEGF、PDGF水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the efficacy of leizumab combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma (NVG) and its effects on ocular artery hemodynamics, serum vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Methods: 60 cases (94 eyes) of NVG patients who were treated in department of Ophthalmology, Union Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology from April 2018 to February 2021 were selected. The patients were randomly divided into control group and study group by random number table method, 30 cases (48 eyes) and 30 cases (46 eyes) respectively. The control group was treated with Ahmed glaucoma valve implantation, and Ahmed glaucoma valve implantation was performed one week after intraocular injection of ramizumab in the study group. The therapeutic effect was observed. The ocular artery hemodynamics, serum VEGF and PDGF were compared between the two groups, and the iris and anterior chamber angle neovascularization regression rate and complication rate were observed. Results: The curative effect in the study group was significantly better than that in the control group (P<0.05). 3 months after treatment, the blood flow resistance coefficient (RI) in the study group was lower than that in the control group, and the peak systolic velocity (PSV) and end diastolic velocity (EDV) were higher than those in the control group (P<0.05). 3 months after treatment, VEGF and PDGF decreased in both groups, and the study group was lower than the control group (P<0.05). 3 months after treatment, intraocular pressure decreased, and visual acuity increased in the two groups, and the improvement degree in the study group was better than that in the control group (P<0.05). The iris and anterior chamber angle neovascularization regression rate in the study group was higher than that in the control group (P<0.05). The incidence of complications in the study group was lower than that in the control group (P<0.05). Conclusion: NVG is treated with Ahmed glaucoma valve implantation combined with ralizumab, which can effectively restore vision and intraocular pressure, and has a better efficacy, which may be related to the improvement of ocular arterial hemodynamics and serum VEGF and PDGF levels by combined treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
